Trial Profile

Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teclistamab (Primary) ; Dexamethasone; Lenalidomide
Indications Smoldering multiple myeloma
Focus Therapeutic Use
Acronyms Immuno-PRISM

Most Recent Events

14 Jun 2026 Results presented in a Dana-Farber Cancer Institute Media Release.
14 Jun 2026 According to Dana-Farber Cancer Institute Media Release, results from this trial presented in a late-breaking session at the European Hematology Association Congress in Stockholm, Sweeden, June 11 to 14.
18 Jul 2024 Planned number of patients changed from 51 to 52.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com